Key statistics
On Monday, Annexon Inc (ANNX:NSQ) closed at 6.14, -26.90% below its 52-week high of 8.40, set on Mar 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.31 |
---|---|
High | 6.34 |
Low | 6.06 |
Bid | 6.05 |
Offer | 6.43 |
Previous close | 6.29 |
Average volume | 1.10m |
---|---|
Shares outstanding | 105.65m |
Free float | 97.83m |
P/E (TTM) | -- |
Market cap | 664.56m USD |
EPS (TTM) | -1.22 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 21:00 BST.
More ▼
Announcements
- Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
- Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress
- Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio
- Annexon Biosciences to Participate in Upcoming September Investor Conferences
- Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
- Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy
- Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
- Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
- Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
- Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting
More ▼